Horst Rose
Directeur/Membre du Conseil chez ImVision Therapeutics, Inc.
Profil
Horst Rose is currently a Director at ImVision Therapeutics, Inc. He was previously the Chief Executive Officer at Elégance GmbH, Director-Operations at ImVisioN GmbH, Physiology Professor at RWTH Aachen University, Head-Medical Research at Biovision AG, and Chief Operating & Human Resources Officer at ImVisioN Therapeutics AG.
He was also the Head-Research & Development at Abbott Products GmbH.
Dr. Rose received his undergraduate and doctorate degrees from RWTH Aachen University.
Postes actifs de Horst Rose
| Sociétés | Poste | Début |
|---|---|---|
ImVision Therapeutics, Inc.
 ImVision Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImVision Therapeutics, Inc. develops proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. The company was founded on January 28, 2005 and is headquartered in Hanover, Germany. | Directeur/Membre du Conseil | - |
Anciens postes connus de Horst Rose
| Sociétés | Poste | Fin |
|---|---|---|
ImVisioN Therapeutics AG
 ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future. | Directeur des opérations | 13/02/2014 |
| Biovision AG | Directeur Technique/Scientifique/R&D | 01/01/2005 |
| Abbott Products GmbH | Directeur Technique/Scientifique/R&D | 01/01/2002 |
| RWTH Aachen University | Corporate Officer/Principal | - |
Elégance GmbH
 Elégance GmbH Catalog/Specialty DistributionRetail Trade Elégance GmbH provides mail-order services. The company was founded in 1938 and is headquartered in Aachen, Germany. | Directeur Général | - |
Formation de Horst Rose
| RWTH Aachen University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
ImVisioN GmbH
 ImVisioN GmbH Miscellaneous Commercial ServicesCommercial Services ImVisioN GmbH provides research in intralymphatic immunotherapy. It is a biotechnology company which specializes the use of intralymphatic immunotherapy to develop treatments for major allergies. Its product, IVN201, is a MAT immunotherapeutic that targets cat dander allergy, a common allergy inadequately addressed by available therapeutic interventions. The company was founded in 2005 and is headquartered in Hanover, Germany. | Commercial Services |
ImVisioN Therapeutics AG
ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future. | Commercial Services |
| Biovision AG | |
| Abbott Products GmbH | |
Elégance GmbH
Elégance GmbH Catalog/Specialty DistributionRetail Trade Elégance GmbH provides mail-order services. The company was founded in 1938 and is headquartered in Aachen, Germany. | Retail Trade |
ImVision Therapeutics, Inc.
ImVision Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImVision Therapeutics, Inc. develops proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. The company was founded on January 28, 2005 and is headquartered in Hanover, Germany. | Health Technology |